×
Zymeworks EBIT Margin 2016-2025 | ZYME
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
Zymeworks ebit margin from 2016 to 2025. Ebit margin can be defined as earnings before interest and taxes as a portion of total revenues
View More
Zymeworks EBIT Margin 2016-2025 | ZYME
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
Zymeworks ebit margin from 2016 to 2025. Ebit margin can be defined as earnings before interest and taxes as a portion of total revenues
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$241.7B
Amgen (AMGN)
$155.8B
Gilead Sciences (GILD)
$149.1B
Vertex Pharmaceuticals (VRTX)
$101.5B
Bristol Myers Squibb (BMY)
$97.4B
CSL (CSLLY)
$86.1B
GSK (GSK)
$79.8B
Regeneron Pharmaceuticals (REGN)
$59.5B
Alnylam Pharmaceuticals (ALNY)
$56.7B
Argenex SE (ARGX)
$39.6B
BioNTech SE (BNTX)
$27.1B
Insmed (INSM)
$26B
Royalty Pharma (RPRX)
$20.5B
Biogen (BIIB)
$19.8B
Incyte (INCY)
$16.8B
Illumina (ILMN)
$15.5B
Genmab (GMAB)
$14.5B
Genmab (GNMSF)
$14.3B
Ascendis Pharma (ASND)
$11.7B
BioMarin Pharmaceutical (BMRN)
$11.2B
QIAGEN (QGEN)
$10.9B
Moderna (MRNA)
$10.5B
Exelixis (EXEL)
$10.4B
Swedish Orphan Biovitrum (BIOVF)
$10.3B
Verona Pharma American Depositary Share (VRNA)
$9B
Bio-Techne Corp (TECH)
$8.6B
Exact Sciences (EXAS)
$8.5B
Blueprint Medicines (BPMC)
$8.3B
Roivant Sciences (ROIV)
$8.1B
Halozyme Therapeutics (HALO)
$8B